Pinnacle Investment Management Ltd bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM – Free Report) during the second quarter, HoldingsChannel.com reports. The fund bought 1,200 shares of the company’s stock, valued at approximately $76,000. Tempus AI makes up about 0.4% of Pinnacle Investment Management Ltd’s holdings, making the stock its 13th largest holding.
Other hedge funds have also recently modified their holdings of the company. Pathway Capital Management LP bought a new position in shares of Tempus AI during the first quarter valued at approximately $8,576,000. SeaCrest Wealth Management LLC bought a new position in shares of Tempus AI during the first quarter valued at approximately $535,000. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 31.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company’s stock valued at $205,284,000 after buying an additional 1,016,384 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Tempus AI by 92.6% during the first quarter. Massachusetts Financial Services Co. MA now owns 578,890 shares of the company’s stock valued at $27,926,000 after buying an additional 278,311 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Tempus AI in the first quarter worth approximately $1,019,000. Institutional investors own 24.22% of the company’s stock.
Insider Transactions at Tempus AI
In related news, EVP Erik Phelps sold 3,664 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total value of $273,517.60. Following the completion of the sale, the executive vice president owned 94,115 shares in the company, valued at approximately $7,025,684.75. This trade represents a 3.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 332,500 shares of the business’s stock in a transaction on Thursday, September 25th. The stock was sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the completion of the transaction, the chief executive officer owned 9,141,032 shares of the company’s stock, valued at approximately $699,837,409.92. This trade represents a 3.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 933,662 shares of company stock worth $67,909,393 in the last three months. Company insiders own 26.27% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Report on Tempus AI
Tempus AI Trading Up 9.0%
TEM stock opened at $87.99 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $97.79. The stock has a market cap of $15.29 billion, a price-to-earnings ratio of -73.94 and a beta of 4.89. The business’s 50-day moving average is $73.92 and its 200 day moving average is $62.59.
Tempus AI (NASDAQ:TEM – Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $314.64 million for the quarter, compared to analyst estimates of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The business’s revenue was up 89.5% on a year-over-year basis. During the same period last year, the company posted ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.
About Tempus AI
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
- Five stocks we like better than Tempus AI
- What is the Dow Jones Industrial Average (DJIA)?
- Datavault AI: The New AI Contender Backed by Big Funding
- What Are Dividend Achievers? An Introduction
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- Investing in Travel Stocks Benefits
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.